AntiCD20 mAbs: modifying therapeutic strategies and outcomes in the treatment of lymphoma patients.
about
Immune response in silico (IRIS): immune-specific genes identified from a compendium of microarray expression data.Targeted therapy for hematologic malignancies.Rituximab for the treatment of diffuse large B-cell lymphomas.Fully human antibody exhibits pan-human leukocyte antigen-DR recognition and high in vitro/vivo efficacy against human leukocyte antigen-DR-positive lymphomas.
P2860
AntiCD20 mAbs: modifying therapeutic strategies and outcomes in the treatment of lymphoma patients.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
AntiCD20 mAbs: modifying thera ...... reatment of lymphoma patients.
@ast
AntiCD20 mAbs: modifying thera ...... reatment of lymphoma patients.
@en
AntiCD20 mAbs: modifying thera ...... reatment of lymphoma patients.
@nl
type
label
AntiCD20 mAbs: modifying thera ...... reatment of lymphoma patients.
@ast
AntiCD20 mAbs: modifying thera ...... reatment of lymphoma patients.
@en
AntiCD20 mAbs: modifying thera ...... reatment of lymphoma patients.
@nl
prefLabel
AntiCD20 mAbs: modifying thera ...... reatment of lymphoma patients.
@ast
AntiCD20 mAbs: modifying thera ...... reatment of lymphoma patients.
@en
AntiCD20 mAbs: modifying thera ...... reatment of lymphoma patients.
@nl
P2860
P356
P1476
AntiCD20 mAbs: modifying thera ...... reatment of lymphoma patients.
@en
P2093
Antonio J Grillo-López
P2860
P304
P356
10.1586/14737140.2.3.323
P577
2002-06-01T00:00:00Z